BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37956929)

  • 21. Intranasal delivery of cancer-targeting doxorubicin-loaded PLGA nanoparticles arrests glioblastoma growth.
    Chung K; Ullah I; Kim N; Lim J; Shin J; Lee SC; Jeon S; Kim SH; Kumar P; Lee SK
    J Drug Target; 2020 Jul; 28(6):617-626. PubMed ID: 31852284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.
    Wiwatchaitawee K; Quarterman JC; Geary SM; Salem AK
    AAPS PharmSciTech; 2021 Feb; 22(2):71. PubMed ID: 33575970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.
    Kim M; Ma DJ; Calligaris D; Zhang S; Feathers RW; Vaubel RA; Meaux I; Mladek AC; Parrish KE; Jin F; Barriere C; Debussche L; Watters J; Tian S; Decker PA; Eckel-Passow JE; Kitange GJ; Johnson AJ; Parney IF; Anastasiadis PZ; Agar NYR; Elmquist WF; Sarkaria JN
    Mol Cancer Ther; 2018 Sep; 17(9):1893-1901. PubMed ID: 29970480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
    Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
    J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug delivery approaches for the treatment of glioblastoma multiforme.
    Fakhoury M
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.
    Gravina GL; Mancini A; Marampon F; Colapietro A; Delle Monache S; Sferra R; Vitale F; Richardson PJ; Patient L; Burbidge S; Festuccia C
    J Hematol Oncol; 2017 Jan; 10(1):5. PubMed ID: 28057017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apelin Controls Angiogenesis-Dependent Glioblastoma Growth.
    Frisch A; Kälin S; Monk R; Radke J; Heppner FL; Kälin RE
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32545380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: A nanotechnological approach.
    Agarwal S; Muniyandi P; Maekawa T; Kumar DS
    Int J Pharm; 2018 Nov; 551(1-2):339-361. PubMed ID: 30236647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery.
    Brar HK; Jose J; Wu Z; Sharma M
    Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma.
    D'Amico R; Lei L; Kennedy BC; Sisti J; Ebiana V; Crisman C; Christensen JG; Gil O; Rosenfeld SS; Canoll P; Bruce JN
    Neurol Res; 2012 Apr; 34(3):252-61. PubMed ID: 22449730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of new protein drug delivery system (PDDS) with photoactive compounds as a potential application in the treatment of glioblastoma brain cancer.
    de Melo MT; Piva HL; Tedesco AC
    Mater Sci Eng C Mater Biol Appl; 2020 May; 110():110638. PubMed ID: 32204072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
    Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
    Eur J Med Chem; 2018 Jan; 144():1-28. PubMed ID: 29247857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).
    Hutterer M; Nowosielski M; Haybaeck J; Embacher S; Stockhammer F; Gotwald T; Holzner B; Capper D; Preusser M; Marosi C; Oberndorfer S; Moik M; Buchroithner J; Seiz M; Tuettenberg J; Herrlinger U; Wick A; Vajkoczy P; Stockhammer G
    Neuro Oncol; 2014 Jan; 16(1):92-102. PubMed ID: 24311637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiangiogenic therapies in glioblastoma multiforme.
    McNamara MG; Mason WP
    Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach.
    Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Iser IC; Lenz GS; de Oliveira FH; Venturin G; Greggio S; daCosta JC; Wink MR; Sevigny J; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
    Mol Neurobiol; 2020 Feb; 57(2):635-649. PubMed ID: 31407144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Focused Ultrasound-Mediated Blood-Brain Barrier Opening Increases Delivery and Efficacy of Etoposide for Glioblastoma Treatment.
    Wei HJ; Upadhyayula PS; Pouliopoulos AN; Englander ZK; Zhang X; Jan CI; Guo J; Mela A; Zhang Z; Wang TJC; Bruce JN; Canoll PD; Feldstein NA; Zacharoulis S; Konofagou EE; Wu CC
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):539-550. PubMed ID: 33346092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
    Wang D; Wang C; Wang L; Chen Y
    Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stimuli-Responsive Multifunctional Nanomedicine for Enhanced Glioblastoma Chemotherapy Augments Multistage Blood-to-Brain Trafficking and Tumor Targeting.
    Martins C; Araújo M; Malfanti A; Pacheco C; Smith SJ; Ucakar B; Rahman R; Aylott JW; Préat V; Sarmento B
    Small; 2023 Jun; 19(22):e2300029. PubMed ID: 36852650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.